Draft:Barinthus Biotherapeutics
| Submission declined on 28 November 2023 by Stuartyeates (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 14 November 2023 by WikiOriginal-9 (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
| |
Comment: Not enough independent coverage in secondary sources. Stuartyeates (talk) 19:31, 28 November 2023 (UTC)
- Comment: This is an update to Vaccitech following company renaming. DoubleGrazing (talk) 14:31, 14 November 2023 (UTC)
| Company type | Public |
|---|---|
| Nasdaq: BRNS | |
| Industry | Immunotherapy Biotechnology |
| Founded | 2016 |
| Founder | |
| Headquarters | , |
| Website | barinthusbio |
Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing immunotherapies for chronic infectious diseases, autoimmunity and cancers such as hepatitis B, HPV, celiac disease and prostate cancer. In November 2023, the company announced that it had rebranded from Vaccitech to Barinthus Biotherapeutics plc.[1]
Technology[edit]
The company's platforms include Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two viral vectors which safely mimic viral infection in human cells and elicit antibody and T cell responses to pathogens and tumours, as well as two SNAP synthetic platforms, SNAP-TI (SNAP-Tolerance Immunotherapy) and SNAP-CI (SNAP-Cancer Immunotherapy), previously referred to collectively as SNAPvaxTM.
History[edit]
The company was founded in 2016 as Vaccitech, a University spin-off by Sarah Gilbert and Adrian V. S. Hill at The Jenner Institute, University of Oxford.[2][3][4]
Barinthus Bio has been financed and supported by M&G Catalyst, Google Ventures (GV), Fosun International, Tencent, Huawei, Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).[5][6] [7]
In early 2020, Barinthus Bio, then known as Vaccitech, and the University of Oxford co-invented a vaccine for COVID-19 using the ChAdOx platform.[8]
COVID-19 vaccine[edit]
In July 2020, it was reported that people in Brazil, South Africa and the US had been recruited to populate the vaccine trials.[9]
In July 2020, Barinthus Bio scientists reported in The Lancet a "single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein." Several subjects needed prophylactic paracetamol to minimize their adverse reactions.
Listing on NASDAQ[edit]
Barinthus Bio, then known as Vaccitech, held an initial public offering of shares in 2021, listing on NASDAQ on 30 April 2021 under the symbol VACC, now BRNS.[10]
References[edit]
- ^ "Vaccitech rebrands as Barinthus Biotherapeutics". thepharmaletter.com. Retrieved 28 November 2023.
- ^ Anon (2019). "Vaccitech Ltd". bloomberg.com. Bloomberg News.
- ^ Anon (2016). "Universal flu vaccine under development by Oxford spinout Vaccitech". ox.ac.uk. University of Oxford.
- ^ Anon (2019). "Vaccitech secures £20m Series A with GV, OSI and Sequoia China". innovation.ox.ac.uk. Oxford University Innovation.
- ^ Anon (2019). "About Vaccitech". vaccitech.co.uk. Vaccitech Limited.
- ^ "Inside the Chinese companies developing a Covid-19 vaccine". The Week. 3 September 2020.
- ^ Anon (2021). "M&G leads $168 million Vaccitech financing". mandgplc.com. M&G plc.
- ^ Boseley, Sarah (1 July 2020). "Oxford offers best hope for Covid-19 vaccine this year, MPs told". Guardian News & Media Limited.
- ^ "Vaccitech prices shares at IPO". Reuters. 30 April 2021.
Category:British companies established in 2016 Category:Companies based in Oxford Category:Biotechnology companies of the United Kingdom Category:Biotechnology companies established in 2016 Category:COVID-19 vaccine producers Category:Medical research Category:Companies listed on the Nasdaq